BioCryst Pharmaceuticals
BCRX
103 hedge funds and large institutions have $425M invested in BioCryst Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 22 closing their positions.
104% more call options, than puts
Call options by funds: $895K | Put options by funds: $438K
6% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 33
4% less capital invested
Capital invested by funds: $443M → $425M (-$18.6M)
1.44% less ownership
Funds ownership: 91.78% → 90.34% (-1.4%)
11% less funds holding
Funds holding: 116 → 103 (-13)
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.65M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$4.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.14M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$16.6M |
| 2 |
Millennium Management
New York
|
-$5.24M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.58M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.42M |
| 5 |
AG
Artal Group
Luxembourg
|
-$2.46M |
BCRX Hedge Fund Activity: Q1 2018 in Review
103 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2018, worth a combined $425M — down 4.2% from $443M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of BCRX and 10 opened new positions — a net loss of 12 holders — while 33 trimmed existing stakes and 35 added.
The largest buyer was Great Point Partners, adding an estimated $14M. The largest seller was RTW Investments, exiting entirely with an estimated $16.6M sold.
- 103 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2018, down from 116 in Q4 2017.
- Funds reported $425M of BioCryst Pharmaceuticals stock for Q1 2018, down 4.2% quarter-over-quarter.
- 10 funds opened new BioCryst Pharmaceuticals positions in Q1 2018 and 22 closed out, a net change of -12 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2018 was Great Point Partners, an estimated $14M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2018 was RTW Investments, an estimated $16.6M sold.
Based on aggregated 13F filings for Q1 2018.